Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 2Sarcoma 1Leiomyosarcoma 1

Interventions

Doxorubicin 25Ifosfamide 22Radiotherapy 17Etoposide 11Vincristine 10Cyclophosphamide 10Filgrastim 8Dactinomycin 8Trabectedin 7Chemotherapy, Adjuvant 5pazopanib 4Cisplatin 4Topotecan 3Radiation 3Neoadjuvant Therapy 3Irinotecan 3Granulocyte Colony-Stimulating Factor 3Dacarbazine 3sargramostim 2etoposide phosphate 2eribulin 2Observation 2Methotrexate 2Mesna 2Imatinib Mesylate 2Gemcitabine 2Epirubicin 2Docetaxel 2Dexrazoxane 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Sarcoma × ADI PEG20 × Clear all
NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡